Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease

Nature Neuroscience

Volumn 10, Issue 11, 2007, Pages 1355-1360

  Lobsiger, Christian S ^a   Cleveland, Don W ^a  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAXIN 7; GLUTAMIC ACID;

AMYOTROPHIC LATERAL SCLEROSIS; ASTROCYTE; CELL POPULATION; CENTRAL NERVOUS SYSTEM; DEGENERATIVE DISEASE; GLIA CELL; HUNTINGTON CHOREA; MACROPHAGE; MICROGLIA; NERVE CELL; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PURKINJE CELL; REVIEW; SPINOCEREBELLAR DEGENERATION;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; HUMANS; MODELS, BIOLOGICAL; NEURODEGENERATIVE DISEASES; NEUROGLIA;

EID: 35549006420     PISSN: 10976256     EISSN: None     Source Type: Journal    
DOI: 10.1038/nn1988     Document Type: Review

References (50)

1. Forman, M.S., Trojanowski, J.Q. & Lee, V.M. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat. Med. 10, 1055-1063 (2004).
2. Shin, J.Y. et al. Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J. Cell Biol. 171, 1001-1012 (2005).
3. Custer, S.K. et al. Bergmann glia expression of polyglutamine-expanded ataxin-7 produces neurodegeneration by impairing glutamate transport. Nat. Neurosci. 9, 1302-1311 (2006).
4. Di Giorgio, F.P., Carrasco, M.A., Siao, M.C., Maniatis, T. & Eggan, K. Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. Nat. Neurosci. 10, 608-614 (2007).
5. Nagai, M. et al. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat. Neurosci. 10, 615-622 (2007).
6. Yazawa, I. et al. Mouse model of multiple system atrophy α-synuclein expression in oligodendrocytes causes glial and neuronal degeneration. Neuron 45, 847-859 (2005).
7. Beers, D.R. et al. Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA 103, 16021-16026 (2006).
8. Boillee, S. et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 312, 1389-1392 (2006).
9. Liberatore, G.T. et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat. Med. 5, 1403-1409 (1999).
10. Maragakis, N.J. & Rothstein, J.D. Mechanisms of disease: astrocytes in neurodegenerative disease. Nat. Clin. Pract. Neurol. 2, 679-689 (2006).
11. Block, M.L., Zecca, L. & Hong, J.S. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat. Rev. Neurosci. 8, 57-69 (2007).
12. Boillee, S., Vande Velde, C. & Cleveland, D.W. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 52, 39-59 (2006).
13. Bruijn, L.I. et al. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 18, 327-338 (1997).
14. Howland, D.S. et al. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc. Natl. Acad. Sci. USA 99, 1604-1609 (2002).
15. Wang, J. et al. Coincident thresholds of mutant protein for paralytic disease and protein aggregation caused by restrictively expressed superoxide dismutase cDNA. Neurobiol. Dis. 20, 943-952 (2005).
16. Bruijn, L.I. et al. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 281, 1851-1854 (1998).
17. Lino, M.M., Schneider, C. & Caroni, P. Accumulation of SOD1 mutants in postnatal motoneurons does not causemotoneuron pathology or motoneuron disease. J. Neurosci. 22, 4825-4832 (2002).
18. Pramatarova, A., Laganiere, J., Roussel, J., Brisebois, K. & Rouleau, G.A. Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment. J. Neurosci. 21, 3369-3374 (2001).
19. Clement, A.M. et al. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 302, 113-117 (2003).
20. Ralph, G.S. et al. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat. Med. 11, 429-433 (2005).
21. Miller, T.M. et al. Virus-delivered small RNA silencing sustains strength in amyotrophic lateral sclerosis. Ann. Neurol. 57, 773-776 (2005).
22. Zhu, S. et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417, 74-78 (2002).
23. Bristol, L.A. & Rothstein, J.D. Glutamate transporter gene expression in amyotrophic lateral sclerosis motor cortex. Ann. Neurol. 39, 676-679 (1996).
24. Rothstein, J.D. et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433, 73-77 (2005).
25. Gong, Y.H., Parsadanian, A.S., Andreeva, A., Snider, W.D. & Elliott, J.L. Restricted expression of G86R Cu/Zn superoxide dismutase in astrocytes results in astrocytosis but does not cause motoneuron degeneration. J. Neurosci. 20, 660-665 (2000).
26. Raoul, C. et al. Chronic activation in presymptomatic amyotrophic lateral sclerosis (ALS) mice of a feedback loop involving Fas, Daxx, and FasL. Proc. Natl. Acad. Sci. USA 103, 6007-6012 (2006).
27. Pehar, M. et al. Astrocytic production of nerve growth factor in motor neuron apoptosis: implications for amyotrophic lateral sclerosis. J. Neurochem. 89, 464-473 (2004).
28. Weydt, P., Yuen, E.C., Ransom, B.R. & Moller, T. Increased cytotoxic potential of microglia from ALS-transgenic mice. Glia 48, 179-182 (2004).
29. Gowing, G., Dequen, F., Soucy, G. & Julien, J.P. Absence of tumor necrosis factor-α does not affect motor neuron disease caused by superoxide dismutase 1 mutations. J. Neurosci. 26, 11397-11402 (2006).
30. Son, M., Fathallah-Shaykh, H.M. & Elliott, J.L. Survival in a transgenic model of FALS is independent of iNOS expression. Ann. Neurol. 50, 273 (2001).
31. Wu, D.C., Re, D.B., Nagai, M., Ischiropoulos, H. & Przedborski, S. The inflammatory NADPH oxidase enzyme modulates motor neuron degeneration in amyotrophic lateral sclerosis mice. Proc. Natl. Acad. Sci. USA 103, 12132-12137 (2006).
32. Urushitani, M. et al. Chromogranin-mediated secretion of mutant superoxide dismutase proteins linked to amyotrophic lateral sclerosis. Nat. Neurosci. 9, 108-118 (2006).
33. Urushitani, M., Ezzi, S.A. & Julien, J.P. Therapeutic effects of immunization with mutant superoxide dismutase in micemodels of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA 104, 2495-2500 (2007).
34. Taroni, F. & DiDonato, S. Pathways to motor incoordination: the inherited ataxias. Nat. Rev. Neurosci. 5, 641-655 (2004).
35. Bellamy, T.C. Interactions between Purkinje neurones and Bergmann glia. Cerebellum 5, 116-126 (2006).
36. Yvert, G. et al. Expanded polyglutamines induce neurodegeneration and trans-neuronal alterations in cerebellum and retina of SCA7 transgenic mice. Hum. Mol. Genet. 9, 2491-2506 (2000).
37. Burright, E.N. et al. SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat. Cell 82, 937-948 (1995).
38. Yvert, G. et al. SCA7 mouse models show selective stabilization of mutant ataxin-7 and similar cellular responses in different neuronal cell types. Hum. Mol. Genet. 10, 1679-1692 (2001).
39. Yoo, S.Y. et al. SCA7 knockinmicemodel human SCA7 and reveal gradual accumulation of mutant ataxin-7 in neurons and abnormalities in short-term plasticity. Neuron 37, 383-401 (2003).
40. Garden, G.A. et al. Polyglutamine-expanded ataxin-7 promotes non-cell-autonomous Purkinje cell degeneration and displays proteolytic cleavage in ataxic transgenic mice. J. Neurosci. 22, 4897-4905 (2002).
41. Dauer, W. & Przedborski, S. Parkinson's disease: mechanisms and models. Neuron 39, 889-909 (2003).
42. Croisier, E. & Graeber, M.B. Glial degeneration and reactive gliosis in alpha-synucleinopathies: the emerging concept of primary gliodegeneration. Acta Neuropathol. (Berl.) 112, 517-530 (2006).
43. Masliah, E. et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287, 1265-1269 (2000).
44. Du, Y. et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc. Natl. Acad. Sci. USA 98, 14669-14674 (2001).
45. Zoghbi, H.Y. & Orr, H.T. Glutamine repeats and neurodegeneration. Annu. Rev. Neurosci. 23, 217-247 (2000).
46. Gu, X. et al. Pathological cell-cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice. Neuron 46, 433-444 (2005).
47. Gu, X. et al. Pathological cell-cell interactions are necessary for striatal pathogenesis in a conditional mouse model of Huntington's disease. Mol. Neurodegener. 2, 8 (2007).
48. Sapp, E. et al. Early and progressive accumulation of reactive microglia in the Huntington disease brain. J. Neuropathol. Exp. Neurol. 60, 161-172 (2001).
49. Chen, M. et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat. Med. 6, 797-801 (2000).
50. Miller, T.M. et al. Gene transfer demonstrates that muscle is not a primary target for non-cell-autonomous toxicity in familial amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA 103, 19546-19551 (2006).